Your session is about to expire
← Back to Search
Poly-ADP Ribose Polymerase Inhibitor
RP-3467 + Olaparib for Cancer (POLAR Trial)
Phase 1
Recruiting
Research Sponsored by Repare Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Next generation sequencing (NGS) report demonstrating eligible tumor biomarker
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Must not have
Uncontrolled, symptomatic brain metastases
Presence of other known active invasive cancers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 months
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test the safety and effectiveness of a new drug called RP-3467 alone or in combination with another drug called olaparib in adults with advanced solid tumors.
Who is the study for?
This trial is for adults with advanced solid tumors that have specific molecular characteristics. Participants must meet certain health standards and not be receiving other cancer treatments.
What is being tested?
The study tests the safety and effects of RP-3467, a new potential cancer drug, both alone and combined with Olaparib, an existing treatment. It's to see how these drugs work in patients with advanced tumors.
What are the potential side effects?
Possible side effects may include nausea, fatigue, blood count changes, or allergic reactions related to RP-3467 or Olaparib. The exact side effects will be monitored throughout the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My tumor has a specific marker found by advanced genetic testing.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My cancer has not responded to treatment and there are no standard options left.
Select...
I am 18 years or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have brain metastases that are not well-managed and cause symptoms.
Select...
I do not have any other active invasive cancers.
Select...
I have been diagnosed with MDS or AML.
Select...
I have been treated with a Polθ inhibitor that is not RP-3467.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 20 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To assess the safety and tolerability of RP-3467 alone and in combination with olaparib
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Arm2: RP-3467 + Olaparib combinationExperimental Treatment2 Interventions
Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
Group II: Arm 1: RP-3467 monotherapyExperimental Treatment1 Intervention
Eligible participants will be treated with escalating doses of RP-3467 monotherapy
Find a Location
Who is running the clinical trial?
Repare TherapeuticsLead Sponsor
9 Previous Clinical Trials
1,232 Total Patients Enrolled